Uncovering molecular features driving lung adenocarcinoma heterogeneity in patients who formerly smoked.

Patients who had formerly smoked with LUAD harbor heterogeneous tumor biology. These patients can be divided by smoking induced gene expression to inform prognosis and underlying biological characteristics for treatment selection.